Macrophage Phagocytosis in COPD: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Macrophage Phagocytosis in COPD (NCT00298389), a registered phase not stated study. The primary outcome is Phagocytosis of H. Influenzae Concentration.

2. Clinical Question

The scientific motivation described in the registry record is that people with COPD who have frequent chest infections may be more susceptible to infection, and impaired macrophage activity is presented as one possible explanation. The record says that why this susceptibility occurs is not known. The laboratory endpoint addresses a proposed mechanism: macrophages normally remove inhaled debris, which can include bacteria, and the study measures phagocytosis of H. influenzae under in-vitro conditions.

This question is mechanistic rather than a direct test of a clinical outcome. The endpoint does not itself count chest infections, measure COPD progression, or describe how participants felt or functioned. Even if group values were available, a difference in this laboratory measure would need to be interpreted as a difference in the measured assay response, not as direct evidence about infection risk or disease course.

3. Trial Design

The registry record describes a completed study titled “Macrophage Phagocytosis in COPD,” sponsored by Imperial College London. The recorded enrollment is 56. The record lists Chronic Obstructive Pulmonary Disease, Emphysema, and Chronic Bronchitis as conditions. The study start is recorded as 2005-10 and primary completion as 2010-12.

The comparison includes non-smokers, smokers, and patients with stable COPD. Non-smokers are described as having no history of respiratory or allergic disease and normal baseline spirometry. The smoker group is described by a smoking history of at least 10 pack years. The COPD group consists of patients with stable COPD. These descriptions give some group-defining information, but they do not establish that the groups were matched or comparable on other characteristics.

The record identifies the comparison as nonrandomized and states that allocation was not stated. These are not like-for-like control arms. There is no described intervention assigned to participants, and the comparison should not be interpreted as a randomized treatment trial. Group membership is based on the characteristics described in the registry record; the record does not give further recruitment or assignment details.

The primary endpoint is a continuous laboratory measurement: phagocytosis of H. influenzae concentration in relative fluorescence units, assessed at 1 hour. It is described as a mean with standard error. The record lists two outcome measures and two analyses, but it does not identify the additional outcome or provide the analysis details and results needed to understand how each was handled.

The record does not report eligibility criteria beyond the group descriptions, the specific assay procedures, sample collection details, or the number of participants contributing endpoint data in each group. It also does not report a protocol, sample-size justification, or a full statistical analysis plan. These omissions limit assessment of how the recorded groups and measurements relate to the study’s intended comparisons.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Phagocytosis of H. Influenzae Concentration, measured over 1 hour.

The primary endpoint measures phagocytosis of H. influenzae in vitro. Its unit is the relative fluorescence unit, and the recorded timeframe is 1 hour. The endpoint is described as a mean with standard error. The registry record does not provide the group means or standard errors, and it does not specify the endpoint population.

Macrophages are described in the study summary as lung white cells that normally remove inhaled debris, including bacteria. Measuring bacterial phagocytosis gives a laboratory measure relevant to the proposed role of macrophages in susceptibility to chest infections. It can therefore address a biological mechanism that the study is interested in. The registry record does not explain the assay protocol, how fluorescence relates to the amount of phagocytosis, or how the measurement was quality-controlled.

General statistical context: a continuous endpoint retains information about the measured value rather than reducing each participant to a category. Reporting a group mean describes the average assay measurement in that group. A standard error describes the precision of an estimated mean, not the spread of individual participant measurements. It should not be read as a standard deviation.

This is an in-vitro endpoint, not a direct clinical measure. It does not directly report the occurrence of chest infections, COPD worsening, or another patient-level outcome. A group difference, if reported, would describe the assay values in the measured groups. It would not on its own establish that macrophage activity caused differences in clinical susceptibility, especially because the comparison is nonrandomized and the groups are not described as like-for-like controls.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

General statistical context: the endpoint is continuous because it is recorded as a quantitative fluorescence measure. A group mean can describe the average measurement, while a comparison of means can describe how far apart group averages are. The registry record says that the primary measure is reported as a mean with standard error, but it does not report the means, standard errors, or a comparison estimate. Without those values, the magnitude and precision of the observed results cannot be evaluated.

What does a standard error describe?

General statistical context: the standard error is the estimated uncertainty of a statistic, such as a sample mean. It reflects precision of the estimate under the assumptions of the method. It is not the same as the standard deviation, which describes variation among individual observations. A small standard error can accompany substantial variation among participants when the estimate is based on enough observations; conversely, a mean may be imprecise when data are limited or variable. Because the registry record does not state group-level standard errors or the number measured in each group, readers cannot assess the precision of the primary endpoint.

How would a group comparison be interpreted?

General statistical context: a comparison can be expressed as a difference in group means, with uncertainty around that difference. The estimate describes the observed contrast; an interval estimate conveys how uncertain that contrast is under the chosen model. A p-value, if used, describes how compatible the data are with a specified null model under the analysis assumptions. It is not the probability that a hypothesis is true, and it does not convey the size or clinical importance of a difference. The registry record does not report a comparison estimate, interval, or p-value, and it does not identify the statistical test or model.

In this study, group membership is not described as randomized. General statistical context: random allocation can help balance measured and unmeasured baseline factors across study arms, on average. In a nonrandomized group comparison, differences in characteristics may accompany the exposure or condition being compared. Statistical adjustment can address specified measured factors, but it cannot automatically remove bias from unmeasured or poorly measured factors. The registry record does not report whether any adjustment was performed. It therefore does not support attributing a hypothetical group difference solely to smoking history or COPD.

What does the planning framework mean?

The registry record describes a planning illustration based on the observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It says that the effect to detect is a stated fraction of the observed effect. The record also distinguishes planning outputs as participants per arm for ordinary outcomes and total events for time-to-event outcomes. The primary endpoint in this study is continuous, but no numerical planning outputs are reported in the record available for interpretation.

General statistical context: a sample-size calculation is conditional on assumptions about the effect to detect, outcome variability, allocation, and error rates. Changing an assumption can change the planning result. An illustration based on an observed effect is retrospective planning information, not observed power and not evidence that a study had adequate power. The registry record does not report the study’s own sample-size justification, so the illustration should not be read as the protocol’s original design basis.

Why does the comparison structure matter?

The record identifies three groups but the stated planning framework specifies equal allocation between two arms. The record does not say which two groups such an illustration compares, nor does it report a numerical illustration. It would be inappropriate to infer a particular pairwise comparison or treat the three groups as a single two-arm experiment. General statistical context: comparisons among multiple groups may involve several pairwise contrasts or an overall test, and the choice affects the analysis and interpretation. The registry record does not describe which comparisons were planned.

What can be concluded from the available analysis details?

The record lists two analyses but does not describe their methods, estimands, covariates, assumptions, or results. It does not report whether data were transformed, whether model assumptions were checked, or how outliers were handled. These details can matter for a continuous laboratory measure. General statistical context: an analysis method should match the measurement scale and the study design, and its assumptions should be evaluated against the data. Without the method and the underlying estimates, the suitability and robustness of an analysis cannot be assessed.

The endpoint is described as measured at 1 hour, but the registry record does not explain whether there were other measurement times or how repeated measurements, if any, were treated. No repeated-measure analysis should be inferred from the single stated timeframe. The record also does not specify whether the reported mean and standard error are raw or adjusted estimates. Consequently, the endpoint label alone does not establish the exact statistical estimand.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists two outcome measures and two analyses. It does not identify the additional outcome, describe the analyses, or state which outcome or comparison was designated as primary in the analysis plan beyond naming the phagocytosis endpoint as primary. It does not report whether multiple group comparisons were planned or how multiplicity was handled.

General statistical context: when several outcomes or comparisons are examined, the chance of finding an apparently notable result can increase if each is assessed separately without accounting for the full set of analyses. Methods to address multiplicity depend on the scientific question and analysis plan. Because that plan and the comparison results are not reported, it is not possible to assess whether multiplicity affects interpretation of the posted findings.

The record does not describe missing-data frequency, reasons for missing measurements, or a method for handling missing data. It also does not report how many participants contributed to the primary endpoint in each group. The enrollment of 56 is not enough to determine the endpoint analysis sample size. General statistical context: if measurement availability differs across groups or relates to participant characteristics or outcomes, a complete-case analysis may not represent all enrolled participants. Without details on availability and handling, the potential influence of missingness cannot be assessed.

The analysis populations are not reported. The record does not say whether all enrolled participants, only participants with usable assay measurements, or another defined population contributed to the analyses. It does not report exclusions from analysis or their reasons. These omissions prevent assessment of whether the analyzed groups correspond to the stated group definitions or whether participant inclusion could affect comparability.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry record reports no serious adverse events among the non-smokers, smokers, or COPD groups. The recorded numbers at risk are 20 for non-smokers, 17 for smokers, and 19 for COPD. It also reports no other adverse events in these groups and no deaths. These are the event counts recorded for the groups, not estimates of the probability of an event beyond the study record.

General statistical context: a zero count does not prove that an event cannot occur or that risk is absent. It means no event was recorded in the stated group and observation context. The record does not describe the adverse-event collection period, definitions, ascertainment procedures, or completeness of safety reporting. It also does not establish that these group sizes are the same as the numbers contributing to the primary endpoint.

These groups are not randomized treatment arms, and no treatment intervention is described. The adverse-event counts therefore should not be interpreted as a comparative safety test of treatments. The record does not provide a formal between-group safety analysis or uncertainty estimates. The figures are best read as the recorded counts, alongside the stated numbers at risk, with the reporting limitations in mind.

12. What the Result Does, and Does Not, Mean

The registry record describes a study asking whether macrophage phagocytosis differs among non-smokers, smokers, and patients with stable COPD. Its primary endpoint is an in-vitro measurement of H. influenzae phagocytosis concentration in relative fluorescence units at 1 hour. The record establishes what was measured and how the groups were described, but it does not report the primary endpoint values or the statistical comparisons.

Accordingly, the record does not establish whether the groups had similar or different mean measurements. It does not provide the direction or size of a difference, or its precision. No claim about statistical significance can be made from the endpoint description alone. The record also does not report the analysis methods or the number of participants with usable endpoint data in each group.

Even a reported difference in this measure would concern an assay response, not directly the frequency of chest infections, COPD worsening, or another clinical outcome. The study summary presents macrophage function as a possible explanation for susceptibility to infections. A laboratory measurement can be relevant to that hypothesis, but by itself it does not establish a causal pathway or show that a difference in the assay leads to a difference in clinical outcomes.

The nonrandomized group structure further limits causal interpretation. The record says allocation was not stated and the arms are not a like-for-like control comparison. Differences between groups could reflect other characteristics as well as smoking history or COPD status. The record does not report adjustment for such factors, and adjustment would not automatically resolve unmeasured differences.

The appropriate reading is therefore descriptive and limited: the registry record outlines a mechanistic research question, three groups, and a continuous in-vitro endpoint, but does not provide enough outcome or analysis information to assess the primary result. The adverse-event counts are also limited to the recorded counts and do not amount to a comparative treatment-safety assessment.

13. Why This Trial Matters Statistically

This study illustrates a recurring issue in registry-based interpretation: a clearly named endpoint is not the same as a fully reported result. The record identifies the measurement, unit, and timeframe, but does not report group estimates, uncertainty, or the analysis that produced a comparison. Without those elements, readers cannot determine the magnitude or precision of the measured findings.

The design also matters statistically. Non-smokers, smokers, and patients with stable COPD are groups with different defining characteristics, and the record explicitly says that the arms are not a like-for-like control comparison. A group contrast in a nonrandomized study describes an association unless additional design and analysis information supports a stronger interpretation. The record does not report such details.

The endpoint helps focus the scientific question on a proposed mechanism: macrophage phagocytosis of H. influenzae. At the same time, it shows why endpoint interpretation must stay close to what was measured. An in-vitro assay can characterize a laboratory response; it is not interchangeable with infection frequency, COPD progression, or another clinical outcome. The record’s mechanistic rationale does not itself demonstrate a clinical consequence.

There is also a useful distinction between enrollment and analytic information. The registry records enrollment of 56, but does not state how many participants contributed primary endpoint data in each group. Group-specific analysis counts, missing-data information, and the analysis population are important for assessing precision and potential selection effects. These are not reported in the registry record.

Finally, planning illustrations and observed results answer different questions. A sample-size framework based on an observed effect can illustrate assumptions for future planning, but it cannot replace reported estimates and uncertainty or be interpreted as observed power. Because the registry record does not report the observed primary effect or numerical planning results, no conclusion about the study’s precision or adequacy of design can be drawn from that framework alone.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important limitation for interpreting the primary endpoint is that the registry record does not report its numerical results. Group means, standard errors, contrasts, confidence intervals, and p-values are absent. Without them, direction, magnitude, and precision cannot be assessed. The record also does not specify the endpoint population or the number of participants measured in each group.

The group comparison is nonrandomized, allocation is not stated, and the record cautions that the arms are not like-for-like controls. The group descriptions identify differences in smoking history and COPD status, but do not establish comparability on other factors. The record does not report adjusted analyses or enough participant characteristics to evaluate potential confounding.

The endpoint is an in-vitro assay measured at 1 hour. The registry record does not describe the assay protocol, how the fluorescence measure is calibrated or interpreted, or whether the measurement was repeated. It does not report clinical outcomes that would directly connect the laboratory measure to chest infections or disease progression. The study’s mechanistic rationale should therefore not be treated as a demonstrated clinical pathway.

Further limitations include the lack of a reported sample-size justification, full statistical analysis plan, analysis-population definition, missing-data methods, and multiplicity approach. The record lists two outcome measures and two analyses but does not identify all outcomes or explain the analyses. These gaps prevent assessment of whether the reported analysis, if any, followed a prespecified plan or how robust the findings are to alternative methods.

The adverse-event information is limited to counts and numbers at risk. The record does not state the observation period or reporting procedures, and the groups are not treatment arms. Thus, these counts do not establish comparative safety or rule out events outside the recorded context.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Macrophage Phagocytosis in COPD — NCT00298389.
• Registry record last updated 2019-12-03; status last verified 2019-11.
• Results first posted 2019-11-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed study titled “Macrophage Phagocytosis in COPD,” sponsored by Imperial College London. Enrollment is recorded as 56. The start date is 2005-10 and primary completion is 2010-12. Conditions listed are Chronic Obstructive Pulmonary Disease, Emphysema, and Chronic Bronchitis.

The study compares non-smokers, smokers, and patients with stable COPD. The primary endpoint is the mean in-vitro concentration of H. influenzae phagocytosis in relative fluorescence units at 1 hour, reported as a mean with standard error. The comparison is nonrandomized; allocation is not stated, and the record cautions that the arms are not like-for-like controls.

The registry record does not report the primary endpoint values, group-specific analysis counts, comparison estimates, or statistical test results. It lists two outcome measures and two analyses but does not provide their full details. Recorded serious adverse events, other adverse events, and deaths are zero in each group, with the stated group numbers at risk. These counts are not a comparative treatment-safety analysis.